5-May-2023 Results of Meeting

24-Apr-2023 Quarterly Activities/Appendix 4C Cash Flow Report

20-Mar-2023 Bioxyne Executes SPA to Acquire Breathe Life Sciences

27-Feb-2023 Becoming a substantial holder

23-Feb-2023 Half Yearly Report and Accounts

27-Jan-2023 Quarterly Activities/Appendix 4C Cash Flow Report

19-Dec-2022 BXN to Acquire Health & Wellness Co Breathe Life Sciences

30-Nov-2022 New Constitution

28-Nov-2022 Results of Meeting

16-Nov-2022 Cleansing Notice

16-Nov-2022 Application for quotation of securities – BXN

15-Nov-2022 Proposed issue of securities – BXN

3-Nov-2022 Notification of cessation of securities – BXN

31-Oct-2022 Quarterly Activities/Appendix 4C Cash Flow Report

28-Oct-2022 Letter to Shareholders on Annual General Meeting Notice

28-Oct-2022 Notice of Annual General Meeting/Proxy Form

26-Oct-2022 Cleansing Notice

24-Oct-2022 Joins Asian Partner & Sells 49% of Direct Selling Business

30-Sep-2022 Appendix 4G and Corporate Governance Statement

30-Sep-2022 Annual Report to shareholders

30-Aug-2022 Preliminary Final Report

28-Jul-2022 Quarterly Activities/Appendix 4C Cash Flow Report

30-Jun-2022 Initial Director’s Interest Notice

30-Jun-2022 Final Director’s Interest Notice

8-Jun-2022 Board and Management Changes

28-Apr-2022 Quarterly Activities/Appendix 4C Cash Flow Report

22-Feb-2022 Appendix 4D and Interim Report

31-Jan-2022 Quarterly Activities/Appendix 4C Cash Flow Report

30-Nov-2021 Results of Meeting

4-Nov-2021 Reinstatement to Official Quotation

4-Nov-2021 Bioxyne Not to Proceed with Proposed Acquisition

29-Oct-2021 Letter to Shareholders on Annual General Meeting

29-Oct-2021 Notice of Annual General Meeting/Proxy Form

29-Oct-2021 Suspension from Quotation

28-Oct-2021 Quarterly Activities/Appendix 4C Cash Flow Report

27-Oct-2021 Trading Halt

27-Oct-2021 Pause in Trading

30-Sep-2021 Appendix 4G and Corporate Governance Statement

30-Sep-2021 Annual Report to shareholders

30-Sep-2021 Explanatory Note to the 2021 Annual Report

31-Aug-2021 Preliminary Final Report

22-Jul-2021 Quarterly Activities/Appendix 4C Cash Flow Report

30-Apr-2021 Appendix 4C – quarterly

21-Apr-2021 Response to ASX Price Query

25-Feb-2021 Appendix 4D and Half Year Accounts

29-Jan-2021 Appendix 4C – Quarterly December 2020

26-Nov-2020 Results of Meeting

29-Oct-2020 Appendix 4C – quarterly

27-Oct-2020 Notice of Annual General

30-Sep-2020 Appendix 4G and Corporate Governance

30-Sep-2020 Annual Report to shareholders

31-Aug-2020 Preliminary Final Report

21-Aug-2020 Response to ASX Price Query

31-Jul-2020 Appendix 4C – quarterly

1-May-2020 Appendix 4C Revised

30-Apr-2020 Appendix 4C – quarterly

14-Apr-2020 Market Update

28-Feb-2020 Appendix 4D and Half Year Accounts

31-Jan-2020 Appendix 4C – quarterly

20-Jan-2020 Change of Share Registry

27-Nov-2019 Change of Directors Interest Notice X 4

27-Nov-2019 Appendix 3B

25-Nov-2019 Results of Meeting

31-Oct-2019 Appendix 4C – quarterly

25-Oct-2019 Notice of Annual General Meeting/Proxy Form

9-Oct-2019 Change of Director’s Interest Notice

30-Sep-2019 Annual Report to shareholders

30-Sep-2019 Explanatory Note to the 2019 Annual Report

30-Sep-2019 Appendix 4G and Corporate Governance Statement

28-Aug-2019 Preliminary Final Report

31-Jul-2019 Appendix 4C – quarterly

4-Jun-2019 Change of Director’s Interest Notice

29-Apr-2019 Appendix 4C – quarterly

1-Apr-2019 Market Update

20-Feb-2019 Appendix 4D and Half Year Accounts

30-Jan-2019 Appendix 4C – quarterly

21-Jan-2019 Final Director’s Interest Notice

17-Jan-2019 Director Resignation

21-Dec-2018 Change of Directors Interest Notice X 5

21-Dec-2018 Appendix 3B

29-Nov-2018 Results of Meeting

21-Dec-2018 Appendix 3B

29-Nov-2018 Results of Meeting

29-Oct-2018 Quarterly Activities Report

29-Oct-2018 Appendix 4C – quarterly

25-Oct-2018 Notice of Annual General Meeting/Proxy Form

16-Oct-2018 Change of Director’s Interest Notice

28-Sep-2018 Annual Report to shareholders

28-Sep-2018 Appendix 4G and Corporate Governance Statement

25-Sep-2018 Bioxyne Expands to Indonesia with Acquisition

31-Aug-2018 Preliminary Final Report

6-Aug-2018 Change of Director’s Interest Notice

27-Jul-2018 Quarterly Activities and Quarterly Cash Flow Report

16-Jul-2018 Change of Director’s Interest Notice

10-Jul-2018 Change of Director’s Interest Notice

22-Jun-2018 Change of Director’s Interest Notice

20-Jun-2018 Change of Director’s Interest Notice

12-Jun-2018 Bioxyne to Distribute GRAYNS Starch Reducing Rice Cooker

21-May-2018 Clarification to Announcement

21-May-2018 Expands to Thailand, Philippines, Myanmar, Cambodia,

4-May-2018Initial Director’s Interest Notice

1-May-2018 Appointment of Non-Executive Director

30-Apr-2018 Securities Trading Policy – Updated

27-Apr-2018 Quarterly Activities and Quarterly Cash Flow Reports

19-Mar-2018 Investor Update

1-Mar-2018 Response to ASX Query Letter

28-Feb-2018 Appendix 4D and Interim Financial Report

26-Feb-2018 Unique NZ Colostrum Honey Dairy Product for China and S.E.A

16-Feb-2018 Final Director’s Interest Notice

15-Feb-2018 Director Resignation

15-Feb-2018 Appendix 3B Corrected

30-Jan-2018 Quarterly Activities and Quarterly Cash Flow Report Dec 17

17-Jan-2018 Change of Director’s Interest Notice

16-Jan-2018 Additional New Products Launched for Direct Sales

19-Dec-2017 Appendix 3B

14-Dec-2017 Third Party Claim

11-Dec-2017 Appendix 3B

11-Dec-2017 Change of Directors Interest X 3

11-Dec-2017 Positive Bioxyne Gut Health Clinical Trial Results

7-Dec-2017 Change of Directors Interest Notice X 2

7-Dec-2017 Bioxyne Launches NZ Dairy Formula Product in South East Asia

7-Dec-2017 Appendix 3B Amended

5-Dec-2017 Appendix 3B

1-Dec-2017 Change of Share Registry

28-Nov-2017 Results of Meeting

15-Nov-2017 Letter to Optionholders

1-Nov-2017 Change of Director’s Interest Notice

27-Oct-2017 Appendix 3B

26-Oct-2017 Notice of Annual General Meeting/Proxy Form

25-Oct-2017 Quarterly Activities Report and Appendix 4C

25-Oct-2017 Malaysian Direct Selling Licence to Propel Bioxyne into MLM

17-Oct-2017 Appendix 3B

16-Oct-2017 Response to ASX Price Query Letter

12-Oct-2017 Appendix 3B

29-Dec-2016 Details of Company Address

24-Nov-2016 Results of Meeting

23-Nov-2016 AGM Notice – Amendment to Resolutions

21-Nov-2016 AGM – Amendment to Resolutions

18-Nov-2016 Final Director’s Interest Notice

18-Nov-2016 Director Resignation

2-Nov-2016 Launch of Two Products Containing PCC Onto Australian Market

26-Oct-2016 Quarterly Activities Report and Appendix 4C

24-Oct-2016 Notice of Annual General Meeting/Proxy Form

17-Oct-2016 Recruitment for Clinical Trial of Proprietary Probiotic PCC

29-Sep-2016 Annual Report to shareholders

29-Sep-2016 Appendix 4G and Corporate Governance Statement

12-Sep-2016 Becoming a substantial holder

9-Sep-2016 Ceasing to be a substantial holder

1-Sep-2016 Management Restructure

1-Sep-2016 Company Secretary Appointment/Details of Company Address

30-Aug-2016 Appendix 4E – Preliminary Final Report

28-Jul-2016 Appendix 4C – June Quarterly

23-Jun-2016 Bioxyne Commences New Clinical Trial

15-Jun-2016 Directors Equity Based Incentives